The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Published Date: 22 Apr 2024

Compared to chemotherapy, the ALK inhibitor lowered the risk of death or recurrence by 76%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

2.

Assisted Dying Under Scrutiny From Medscape's Readers

3.

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

4.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

5.

Analysis of projected cancer rates in Canada by 2024.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot